Evidence map›Paper›PMID 39353993›Full record

ArticleScientific reports2024

ERBB2 is a potential diagnostic and prognostic biomarker in renal clear cell carcinoma.

Wu-Niri Gao, Li-Gang Chen, Lu-Ri Bao, Ning He, Ta-la Hu, Can Lai, Rui-Feng Xu, Xi-Feng Wang, Jing-Yuan Wang, Jian-Rong Zhao and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wu-Niri Gao *Department of Nephrology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010050, Inner Mongolia, People's Republic of China.
Li-Gang Chen *Department of Urology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, People's Republic of China.
Lu-Ri BaoDepartment of Pathology, School of Basic Medicine, Inner Mongolia Medical University, Hohhot, People's Republic of China.
Ning HeHemodialysis Room, The No. 2 Hospital of Hohhot, Hohhot, People's Republic of China.
Ta-la HuDepartment of Nephrology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010050, Inner Mongolia, People's Republic of China.
Can LaiDepartment of Gastrointestinal Surgery, Inner Mongolia Campus of Peking University Cancer Hospital (The Affiliated Cancer Hospital of Inner Mongolia Medical University), Hohhot, People's Republic of China.
Rui-Feng XuDepartment of Nephrology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010050, Inner Mongolia, People's Republic of China.
Xi-Feng WangHemodialysis Room, The No. 2 Hospital of Hohhot, Hohhot, People's Republic of China.
Jing-Yuan WangDepartment of Pathology, School of Basic Medicine, Inner Mongolia Medical University, Hohhot, People's Republic of China.
Jian-Rong ZhaoDepartment of Nephrology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010050, Inner Mongolia, People's Republic of China.
Yan MengDepartment of Nephrology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010050, Inner Mongolia, People's Republic of China. mbao124@qq.com.

Funding

General Project of Inner Mongolia Natural Science Foundation No. 2022SHZR2291Inner Mongolia Health Science and Technology Project in 2022 No. 202201293Key Research and Development and Achievement Transformation Project in the social welfare field of the 14th five-year plan in the Inner Mongolia Autonomous Region No. 2022YFSH0087National Natural Science Foundation of China No. 81960143Shanghai Key laboratory of Kidney and Blood Purification No. 14DZ226022the "Going far" Talent Program of Inner Mongolia Medical University No. ZY0130015the Science and Technology Commission of Shanghai No. 20DZ2271600the Trinity College Students Innovation and Entrepreneurship Cultivation Project of Inner Mongolia Medical University No. SWYT2020008
6 · The paper itself

Abstract

Renal clear cell carcinoma (ccRCC) is a common parenchymal tumor of the kidney, and the discovery of biomarkers for early and effective diagnosis of ccRCC can improve the early diagnosis of patients and thus improve long-term survival. Erb-b2 receptor tyrosine kinase 2 (ERBB2) mediates the processes of cell proliferation, differentiation, and apoptosis inhibition. The purpose of this study was to investigate the diagnostic and prognostic role of ERBB2 in ccRCC. We analyzed the expression levels of ERBB2 in various cancers from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. RNA-seq data were analyzed using R packages to identify differentially expressed genes between the high and low ERBB2 expression groups in the TCGA-KIRC dataset. Spearman correlation analysis was performed to determine the correlation between ERBB2 expression and immune cell infiltration, immune checkpoint expression, and PTEN expression. DNA methylation changes and genetic alterations in ERBB2 were assessed using the MethSurv and cBioPortal databases. Logistic regression analysis was performed to determine the correlation between ERBB2 expression and the clinicopathological characteristics of ccRCC patients. The diagnostic and prognostic value of ERBB2 was assessed using Kaplan‒Meier (K‒M) survival curves, diagnostic ROC curves, time-dependent ROC curves, nomogram models, and Cox regression models. The expression level of ERBB2 is lower in tumor tissues of ccRCC patients than in the corresponding control tissues. Differentially expressed genes associated with ERBB2 were significantly enriched in the pathways "BMP2WNT4FOXO1 pathway in primary endometrial stromal cell differentiation" and "AMAN pathway". In ccRCC tissues, ERBB2 expression levels were associated with immune cell infiltration, immune checkpoints, and PTEN. The DNA methylation status of 10 CpG islands in the ERBB2 gene was associated with the prognosis of ccRCC. ERBB2 expression levels in ccRCC tissues were associated with race, sex, T stage, M stage, histological grade, and pathological stage. Cox regression analysis showed that ERBB2 was a potential independent predictor of overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in ccRCC patients. ROC curve analysis showed that the expression level of ERBB2 could accurately distinguish between ccRCC tissue and adjacent normal renal tissue. Our study showed that ERBB2 expression in ccRCC tissues can be of clinical importance as a potential diagnostic and prognostic biomarker.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellErb-b2 Receptor Tyrosine KinasesGene Expression Regulation, NeoplasticKidney NeoplasmsAgedDNA MethylationFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisROC CurveBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesClinical outcomeDNA methylationERBB2Immune cell infiltrationRenal clear cell carcinomaTumor prognosis

Identifiers

PMID39353993
PMCPMC11445465

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.